Page 233 - 磁共振成像2024年7期电子刊

综 述｜｜Reviews 磁共振成像 2024年7月第15卷第7期 Chin J Magn Reson Imaging, Jul, 2024, Vol. 15, No. 7

YÜ, X Y, WU H, NIU G M, et al. Multiparameter MRI radiomics platinum resistance in ovarian cancer treatment[J/OL]. Biomedecine
predicts preoperative peritoneal metastasis in patients with epithelial Pharmacother, 2021, 133: 111013 [2024-06-15]. https://linkinghub.elsevier.
ovarian cancer[J]. Chin J Magn Reson Imag, 2021, 12(8): 44-48. DOI: com/retrieve/pii/S0753-3322(20)31205-1. DOI: 10.1016/j.biopha.2020.
10.12015/issn.1674-8034.2021.08.009. 111013.
[24] SONG X L, REN J L, YAO T Y, et al. Radiomics based on [41] LEI R L, YU Y F, LI Q J, et al. Deep learning magnetic resonance
multisequence magnetic resonance imaging for the preoperative prediction imaging predicts platinum sensitivity in patients with epithelial ovarian
of peritoneal metastasis in ovarian cancer[J]. Eur Radiol, 2021, 31(11): cancer[J/OL]. Front Oncol, 2022, 12: 895177 [2024-06-15]. https://www.
8438-8446. DOI: 10.1007/s00330-021-08004-7. frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.895177/full.
[25] WEI M X, ZHANG Y, DING C, et al. Associating peritoneal DOI: 10.3389/fonc.2022.895177.
metastasis with T2-weighted MRI images in epithelial ovarian cancer [42] CALVO E, SESSA C, HARADA G, et al. Phase I study of
using deep learning and radiomics: a multicenter study[J]. J Magn lurbinectedin in combination with weekly paclitaxel with or without
Reson Imaging, 2024, 59(1): 122-131. DOI: 10.1002/jmri.28761. bevacizumab in patients with advanced solid tumors[J]. Invest New
[26] LI J J, ZHANG J N, WANG F, et al. CT-based radiomics for the Drugs, 2022, 40(6): 1263-1273. DOI: 10.1007/s10637-022-01281-z.
preoperative prediction of occult peritoneal metastasis in epithelial [43] MAI J, WU L M, YANG L, et al. Therapeutic strategies targeting folate
ovarian cancers[J]. Acad Radiol, 2024, 31(5): 1918-1930. DOI: 10.1016/ receptor α for ovarian cancer[J/OL]. Front Immunol, 2023, 14:
j.acra.2023.11.032. 1254532 [2024-06-15]. https://www. frontiersin. org/articles/10.3389/
[27] CHEN H Z, WANG X R, ZHAO F M, et al. The development and fimmu.2023.1254532/full. DOI: 10.3389/fimmu.2023.1254532.
validation of a CT-based radiomics nomogram to preoperatively predict [44] QIU D M, CAI W Q, ZHANG Z Q, et al. High Ki-67 expression is
lymph node metastasis in high-grade serous ovarian cancer[J/OL]. Front significantly associated with poor prognosis of ovarian cancer patients:
Oncol, 2021, 11: 711648 [2024-06-15]. https://pubmed. ncbi. nlm. nih. evidence from a meta-analysis[J]. Arch Gynecol Obstet, 2019, 299(5):
gov/34532289/. DOI: 10.3389/fonc.2021.711648. 1415-1427. DOI: 10.1007/s00404-019-05082-3.
[28] QI Y, LIU J C, WANG X Y, et al. Development and validation of an [45] WANG X H, XU C, GRZEGORZEK M, et al. Habitat radiomics
ultrasound‑based radiomics nomogram to predict lymph node status in analysis of pet/ct imaging in high-grade serous ovarian cancer:
patients with high-grade serous ovarian cancer: a retrospective analysis [J/OL]. application to Ki-67 status and progression-free survival[J/OL]. Front
J Ovarian Res, 2024, 17(1): 48 [2024-06-15]. https://pubmed.ncbi.nlm. Physiol, 2022, 13: 948767 [2024-06-15]. https://www. frontiersin. org/
nih.gov/38389075/. DOI: 10.1186/s13048-024-01375-7. articles/10.3389/fphys.2022.948767/full. DOI: 10.3389/fphys.2022.948767.
[29] LENG Y P, KAN A, WANG X W, et al. Contrast-enhanced CT [46] GU R, TAN S Y, XU Y P, et al. CT radiomics prediction of CXCL9
radiomics for preoperative prediction of stage in epithelial ovarian expression and survival in ovarian cancer[J/OL]. J Ovarian Res, 2023,
cancer: a multicenter study[J/OL]. BMC Cancer, 2024, 24(1): 307 16(1): 180 [2024-06-15]. https://ovarianresearch. biomedcentral. com/
[2024-06-15]. https://pubmed.ncbi.nlm.nih.gov/38448945/. DOI: 10.1186/ articles/10.1186/s13048-023-01248-5. DOI: 10.1186/s13048-023-01248-5.
s12885-024-12037-8. [47] XU W T, ZHU C Y, JI D, et al. CT-based radiomics prediction of
[30] LU J J, CAI S Q, WANG F, et al. Development of a prediction model CXCL13 expression in ovarian cancer[J]. Med Phys, 2023, 50(11):
for gross residual in high-grade serous ovarian cancer by combining 6801-6814. DOI: 10.1002/mp.16730.
preoperative assessments of abdominal and pelvic metastases and [48] WAN S, ZHOU T F, CHE R H, et al. CT-based machine learning
multiparametric MRI[J]. Acad Radiol, 2023, 30(9): 1823-1831. DOI: radiomics predicts CCR5 expression level and survival in ovarian
10.1016/j.acra.2022.12.019. cancer[J/OL]. J Ovarian Res, 2023, 16(1): 1 [2024-06-15]. https://
[31] AI Y, ZHANG J D, JIN J B, et al. Preoperative prediction of metastasis for ovarianresearch. biomedcentral. com/articles/10.1186/s13048-022-01089-8.
ovarian cancer based on computed tomography radiomics features and DOI: 10.1186/s13048-022-01089-8.
clinical factors[J/OL]. Front Oncol, 2021, 11: 610742 [2024-06-15]. https:// [49] LU H N, ARSHAD M, THORNTON A, et al. A mathematical-descriptor
pubmed.ncbi.nlm.nih.gov/34178617/. DOI: 10.3389/fonc.2021.610742. of tumor-mesoscopic-structure from computed-tomography images
[32] RUNDO L, BEER L, ESCUDERO SANCHEZ L, et al. Clinically annotates prognostic- and molecular-phenotypes of epithelial ovarian
interpretable radiomics-based prediction of histopathologic response to cancer[J/OL]. Nat Commun, 2019, 10(1): 764 [2024-06-15]. https://
neoadjuvant chemotherapy in high-grade serous ovarian carcinoma[J/OL]. www.nature.com/articles/s41467-019-08718-9. DOI: 10.1038/s41467-019-
Front Oncol, 2022, 12: 868265 [2024-06-15]. https://www.frontiersin. 08718-9.
org/journals/oncology/articles/10.3389/fonc.2022.868265/full. DOI: 10.3389/ [50] FOTOPOULOU C, ROCKALL A, LU H N, et al. Validation analysis
fonc.2022.868265. of the novel imaging-based prognostic radiomic signature in patients
[33] CRISPIN-ORTUZAR M, WOITEK R, REINIUS M A V, et al. undergoing primary surgery for advanced high-grade serous ovarian
Integrated radiogenomics models predict response to neoadjuvant cancer (HGSOC) [J]. Br J Cancer, 2022, 126(7): 1047-1054. DOI:
chemotherapy in high grade serous ovarian cancer[J/OL]. Nat Commun, 10.1038/s41416-021-01662-w.
2023, 14(1): 6756 [2024-06-15]. https://www.nature.com/articles/s41467- [51] LU H N, LOU H T, WENGERT G, et al. Tumor and local lymphoid
023-41820-7. DOI: 10.1038/s41467-023-41820-7. tissue interaction determines prognosis in high-grade serous ovarian
[34] ZHANG K, ABDOLI N, GILLEY P, et al. Developing a novel image cancer[J/OL]. Cell Rep Med, 2023, 4(7): 101092 [2024-06-15]. https://
marker to predict the clinical outcome of neoadjuvant chemotherapy www. ncbi. nlm. nih. gov/pmc/articles/PMC10394173/. DOI: 10.1016/j.
(NACT) for ovarian cancer patients[J/OL]. Comput Biol Med, 2024, xcrm.2023.101092.
172: 108240 [2024-06-15]. https://www.sciencedirect.com/science/article/ [52] RIZZO S, BOTTA F, RAIMONDI S, et al. Radiomics of high-grade
abs/pii/S001048252400324X?via%3Dihub. DOI: 10.1016/j.compbiomed. serous ovarian cancer: association between quantitative CT features,
2024.108240. residual tumour and disease progression within 12 months[J]. Eur
[35] LI Y A, JIAN J M, GE H J, et al. Peritumoral MRI radiomics features Radiol, 2018, 28(11): 4849-4859. DOI: 10.1007/s00330-018-5389-z.
increase the evaluation efficiency for response to chemotherapy in [53] CHEN H Z, WANG X R, ZHAO F M, et al. A CT-based radiomics
patients with epithelial ovarian cancer[J/OL]. J Magn Reson Imaging, nomogram for predicting early recurrence in patients with high-grade
2024 [2024-06-15]. https://onlinelibrary.wiley.com/doi/10.1002/jmri.29359. serous ovarian cancer[J/OL]. Eur J Radiol, 2021, 145: 110018
DOI: 10.1002/jmri.29359. [2024-06-15]. https://www.sciencedirect.com/science/article/abs/pii/S07
[36] VEERARAGHAVAN H, VARGAS H A, JIMENEZ-SANCHEZ A, et al. 20048X2100499X?via%3Dihub. DOI: 10.1016/j.ejrad.2021.110018.
Integrated multi-tumor radio-genomic marker of outcomes in patients with [54] ZHANG H, MAO Y F, CHEN X J, et al. Magnetic resonance imaging
high serous ovarian carcinoma[J/OL]. Cancers, 2020, 12(11): 3403 radiomics in categorizing ovarian masses and predicting clinical
[2024-06-15]. https://www.mdpi.com/2072-6694/12/11/3403. DOI: 10.3390/ outcome: a preliminary study[J]. Eur Radiol, 2019, 29(7): 3358-3371.
cancers12113403. DOI: 10.1007/s00330-019-06124-9.
[37] MAO M M, LI H M, SHI J, et al. Prediction of platinum-based [55] WANG T P, WANG H J, WANG Y D, et al. MR-based
chemotherapy sensitivity for epithelial ovarian cancer by multi-sequence radiomics-clinical nomogram in epithelial ovarian tumor prognosis
MRI-based radiomic nomogram[J]. Zhonghua Yi Xue Za Zhi, 2022, prediction: tumor body texture analysis across various acquisition
102(3): 201-208. DOI: 10.3760/cma.j.cn112137-20210816-01844. protocols[J/OL]. J Ovarian Res, 2022, 15(1): 6 [2024-06-15]. https://
[38] LI H M, CAI S Q, DENG L, et al. Prediction of platinum resistance for ovarianresearch.biomedcentral.com/articles/10.1186/s13048-021-00941-7.
advanced high-grade serous ovarian carcinoma using MRI-based DOI: 10.1186/s13048-021-00941-7.
radiomics nomogram[J]. Eur Radiol, 2023, 33(8): 5298-5308. DOI: [56] YE L, ZHANG Y, YANG X Y, et al. An ovarian cancer susceptible
10.1007/s00330-023-09552-w. gene prediction method based on deep learning methods[J/OL]. Front
[39] BI Q, MIAO K, XU N, et al. Habitat radiomics based on MRI for Cell Dev Biol, 2021, 9: 730475 [2024-06-15]. https://www.frontiersin.
predicting platinum resistance in patients with high-grade serous org/articles/10.3389/fcell.2021.730475/full. DOI: 10.3389/fcell.2021.730475.
ovarian carcinoma: a MulticenterStudy[J]. Acad Radiol, 2024, 31(6): [57] AGHAYOUSEFI R, HOSSEINIYAN KHATIBI S M, ZUNUNI
2367-2380. DOI: 10.1016/j.acra.2023.11.038. VAHED S, et al. A diagnostic miRNA panel to detect recurrence of ovarian
[40] YI X P, LIU Y Z, ZHOU B L, et al. Incorporating SULF1 cancer through artificial intelligence approaches[J]. J Cancer Res Clin
polymorphisms in a pretreatment CT-based radiomic model for predicting Oncol, 2023, 149(1): 325-341. DOI: 10.1007/s00432-022-04468-2.

·226 · https://www.chinesemri.com